iRhythm Technologies (IRTC) 2024 Truist Securities MedTech Conference summary
Event summary combining transcript, slides, and related documents.
2024 Truist Securities MedTech Conference summary
3 Feb, 2026Market overview and growth segments
Ambulatory cardiac monitoring market sees 6.5 million tests annually, growing mid-single digits.
Long-term continuous monitoring is the fastest-growing segment, with 2.5 million tests per year and mid- to high-teens growth.
Holds about 70% share in long-term continuous monitoring, regaining share recently.
MCT segment accounts for 900,000 tests, growing high single digits, with only 7% share.
Opportunity remains to convert 1.5 million short-term Holter tests to long-term monitoring.
Growth drivers and future plans
International expansion planned in 2025, targeting Netherlands, Switzerland, Austria, Spain, and Japan.
International business currently 1% of total, expected to become a significant growth contributor.
Next-gen MCT device, Zio MCT, expected to launch commercially in the second half of 2025.
Primary care channel contributed 21% of registration volume in 2023, growing faster than other channels.
2025 anticipated as a strong year due to new products and expanded market reach.
Strategic partnerships and technology integration
Signify partnership in pilot phase, targeting proactive monitoring for 3 million patients annually.
Epic Aura partnership enables streamlined EHR integration, increasing account stickiness and volume.
EHR integration leads to notable volume increases and high account retention.
Epic Aura's cloud-based integration will allow automatic access for new accounts.
Both partnerships represent a scalable, one-to-many sales model.
Latest events from iRhythm Technologies
- Annual meeting to vote on directors, equity plan, auditor, and executive pay amid strong growth and ESG focus.IRTC
Proxy filing17 Apr 2026 - Key votes include director elections, equity plan approval, and auditor ratification.IRTC
Proxy filing17 Apr 2026 - AI-driven cardiac monitoring, record 2025 revenue, and global expansion fuel strong growth.IRTC
44th Annual J.P. Morgan Healthcare Conference12 Apr 2026 - Proxy covers director elections, new equity plan, auditor change, and strong pay-for-performance.IRTC
Proxy filing6 Apr 2026 - Record 2025 growth, first positive net income, and strong 2026 outlook with margin expansion.IRTC
Q4 202519 Feb 2026 - Q2 revenue up 19.3% to $148M; guidance raised amid strong demand and ongoing regulatory risks.IRTC
Q2 20242 Feb 2026 - 2024 revenue guidance of $578–$588M reflects global growth in AI-driven cardiac monitoring.IRTC
The 44th Annual William Blair Growth Stock Conference1 Feb 2026 - BioIntelliSense deal, FDA remediation, and MCT launch set stage for growth in 2025.IRTC
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Regulatory remediation and international expansion position the business for accelerated growth.IRTC
2024 Wells Fargo Healthcare Conference22 Jan 2026